MXPA04004683A - Derivados de benzotiazoles tal como ligandos de receptores de adenosina. - Google Patents

Derivados de benzotiazoles tal como ligandos de receptores de adenosina.

Info

Publication number
MXPA04004683A
MXPA04004683A MXPA04004683A MXPA04004683A MXPA04004683A MX PA04004683 A MXPA04004683 A MX PA04004683A MX PA04004683 A MXPA04004683 A MX PA04004683A MX PA04004683 A MXPA04004683 A MX PA04004683A MX PA04004683 A MXPA04004683 A MX PA04004683A
Authority
MX
Mexico
Prior art keywords
lower alkyl
disease
compounds
present
receptor ligands
Prior art date
Application number
MXPA04004683A
Other languages
English (en)
Inventor
David Norcross Roger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA04004683A publication Critical patent/MXPA04004683A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de formula general (I), ver formula (I) en donde R es fenilo, piridin-2-ilo, -C(O)-0-alquilo inferior, C(O)-alquilo inferior, -C(O)morfolinilo) -C(O)-NR??2, -C(CH2)nNR??2 o -(CH2)n-O-alquilo inferior, inferior, y R?? puede ser hidrogeno o alquilo inferior; y a las sales de adicion farmaceuticamente aceptables de los mismos. Los compuestos descritos en esta solicitud tienen una buena afinidad al receptor A2A y por lo tanto pueden emplearse en el control o prevencion de enfermedades basadas en la modulacion del sistema de la adenosina, tales como la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, neuroproteccion, esquizofrenia, ansiedad, dolor, deficits respiratorios, depresion, adiccion alas drogas, tales como la anfetamina, cocaina, opioides,etanol, nicotina,cannabinoides, o contra el asma, respuestas alergicas, hipoxia, isquemia, ataques, y abuso de sustancias. Ademas, los compuestos de la presente invencion pueden ser de utilidad como sedantes, relajantes musculares, antipsicoticos, antiepilepticos, anticonvulsivos y agentes cardioprotectores para transtornos tales como la enfermedad de la arteria coronaria y fallo cardiaco.
MXPA04004683A 2001-11-19 2002-11-09 Derivados de benzotiazoles tal como ligandos de receptores de adenosina. MXPA04004683A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01127313 2001-11-19
PCT/EP2002/012543 WO2003043634A1 (en) 2001-11-19 2002-11-09 Benzothiazole derivatives as adenosine receptor ligands

Publications (1)

Publication Number Publication Date
MXPA04004683A true MXPA04004683A (es) 2004-08-12

Family

ID=8179264

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004683A MXPA04004683A (es) 2001-11-19 2002-11-09 Derivados de benzotiazoles tal como ligandos de receptores de adenosina.

Country Status (21)

Country Link
US (1) US6599901B1 (es)
EP (1) EP1448196B1 (es)
JP (1) JP4216192B2 (es)
KR (1) KR100577109B1 (es)
CN (1) CN100346792C (es)
AR (1) AR037528A1 (es)
AT (1) ATE306265T1 (es)
AU (1) AU2002366194B8 (es)
BR (1) BR0214221A (es)
CA (1) CA2467551A1 (es)
DE (1) DE60206652T2 (es)
ES (1) ES2249639T3 (es)
GT (1) GT200200233A (es)
MX (1) MXPA04004683A (es)
PA (1) PA8557901A1 (es)
PE (1) PE20030715A1 (es)
PL (1) PL369470A1 (es)
RU (1) RU2295523C2 (es)
TW (1) TW200407137A (es)
UY (1) UY27543A1 (es)
WO (1) WO2003043634A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
NO346973B1 (en) 2002-12-20 2023-03-20 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
BRPI0414266A (pt) * 2003-09-19 2006-11-07 Hoffmann La Roche derivados de tiazolopiridina como ligandos receptores da adenosina
CA2543707A1 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
ATE457986T1 (de) * 2004-07-22 2010-03-15 Hoffmann La Roche Benzothiazolderivate
MX2007000635A (es) * 2004-07-22 2007-03-07 Hoffmann La Roche Benzotiazoles sustituidos.
ES2273599B1 (es) * 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
WO2008063301A2 (en) * 2006-10-11 2008-05-29 Alpharma, Inc. Pharmaceutical compositions
ES2398312T3 (es) * 2007-04-04 2013-03-15 Merck Sharp & Dohme Corp. Agentes terapéuticos
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
SG10202005916QA (en) 2015-12-22 2020-07-29 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
AU2016379345B2 (en) 2015-12-22 2020-09-17 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) * 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
DE102019110904B4 (de) 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374550D1 (en) 1982-12-21 1987-12-23 Johnsen Jorgensen Plastics Ltd Dispensing container
EP1303272B1 (en) * 2000-06-21 2008-02-13 F. Hoffmann-La Roche Ag Benzothiazole derivatives for the treatment of alzheimer's disease and parkinson's disease

Also Published As

Publication number Publication date
EP1448196A1 (en) 2004-08-25
AR037528A1 (es) 2004-11-17
AU2002366194B8 (en) 2006-11-16
RU2295523C2 (ru) 2007-03-20
ES2249639T3 (es) 2006-04-01
JP4216192B2 (ja) 2009-01-28
CA2467551A1 (en) 2003-05-30
JP2005515980A (ja) 2005-06-02
AU2002366194B2 (en) 2006-10-26
CN100346792C (zh) 2007-11-07
EP1448196B1 (en) 2005-10-12
KR100577109B1 (ko) 2006-05-10
DE60206652D1 (de) 2006-02-23
PA8557901A1 (es) 2003-06-30
DE60206652T2 (de) 2006-06-22
PL369470A1 (en) 2005-04-18
WO2003043634A1 (en) 2003-05-30
BR0214221A (pt) 2004-09-21
UY27543A1 (es) 2003-05-30
AU2002366194A1 (en) 2003-06-10
CN1589146A (zh) 2005-03-02
TW200407137A (en) 2004-05-16
US6599901B1 (en) 2003-07-29
GT200200233A (es) 2003-06-17
PE20030715A1 (es) 2003-08-29
RU2004118423A (ru) 2006-01-10
KR20050044537A (ko) 2005-05-12
ATE306265T1 (de) 2005-10-15

Similar Documents

Publication Publication Date Title
MXPA04004683A (es) Derivados de benzotiazoles tal como ligandos de receptores de adenosina.
YU96502A (sh) Derivati benzotiazola
SG140605A1 (en) Benzothiazole derivatives
TW200612937A (en) 4-hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
JO2286B1 (en) Modified compounds of the adenosine receptor group
DK0975595T3 (da) Kokainanaloger
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
TWI255807B (en) Therapeutic agents
AU9189301A (en) Use of substituted imidazo(1,2-A)pyridine-, imidazo(1,2-A)pyrimidine and imidazo(1,2-A)pyrazine-3-YL-amine derivatives for producing NOS-inhibiting medicaments
AU2804400A (en) Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
BRPI0414266A (pt) derivados de tiazolopiridina como ligandos receptores da adenosina
ATE253918T1 (de) Verwendung von hymenialdisin und dessen derivaten zur herstellung therapeutischer mittel
IL157413A0 (en) Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
DE69912618D1 (de) NEUE THIENO[2,3-d]PYRIMIDINDIONE, VERFAHREN FÜR IHRE HERSTELLUNG UND IHRE VERWENDUNG IN DER THERAPIE
HUP0401201A2 (hu) Flibanserin stabil polimorfja, ipari eljárás előállítására és alkalmazása gyógyszerek előállítására
HUP0300140A2 (en) 8,8a-dihydro-indeno[1,2-d]thiazole derivatives, substituted in position 8a, a method for their production and their use as medicaments
CA2498291A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
MY140167A (en) Substituted benzothiazoles
TW200503691A (en) Therapeutic agents
NZ543632A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MXPA04004308A (es) Derivados de piridina como ligandos del receptor n-metil-d-aspartato (nmda).
WO2001047946A3 (en) GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR
AR037457A1 (es) Compuestos derivados de benzotiazol, su empleo, un procedimiento para prepararlos y medicamentos que los contienen
KR910000647A (ko) 나프틸아미노-및 나프틸옥시- 피리딘아민 및 관련된 화합물, 이의 제조방법 및 이의 피부소염제로서의 용도
AR037792A1 (es) Compuestos derivados de benzotiazol, su uso, un procedimiento para su obtencion y medicamentos que los contienen

Legal Events

Date Code Title Description
FG Grant or registration